Immunovant, Inc. (NASDAQ: IMVT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
36.95
-0.70-1.86%
News
Down 1.9% — Immunovant Q1 2027 Earnings Call: Complete Transcript (Benzinga).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 206.40M | Perf Week | -1.10% |
| Market Cap | 7.63B | Forward P/E | - | EPS next Y | -2.92 | Insider Trans | -0.34% | Shs Float | 79.36M | Perf Month | -17.82% |
| Enterprise Value | 7.22B | PEG | - | EPS next Q | -0.73 | Inst Own | - | Short Float | 7.65% | Perf Quarter | 4.56% |
| Income | -506.00M | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 12.32 | Perf Half Y | 56.24% |
| Sales | 0.00 | P/B | 19.26 | EPS next Y | 0.58% | ROA | -63.13% | Short Interest | 15.78M | Perf YTD | 45.36% |
| Book/sh | 1.92 | P/C | 18.78 | EPS next 5Y | - | ROE | -69.59% | 52W High | 45.42 -18.65% | Perf Year | 144.54% |
| Cash/sh | 1.97 | P/FCF | - | EPS past 3/5Y | - | ROIC | -75.90% | 52W Low | 14.58 153.43% | Perf 3Y | 71.06% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 97.10% | Volatility | 3.30% 3.39% | Perf 5Y | 328.65% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | -2.93% | Oper. Margin | -7877.46% | ATR (14) | 1.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.27 | Sales Y/Y TTM | - | Profit Margin | -7585.86% | RSI (14) | 36.13 | Recom | 2.26 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.27 | EPS Q/Q | -17.19% | SMA20 | -7.36% | Beta | 0.82 | Target Price | 40.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -8.00% | Rel Volume | 2.38 | Prev Close | 37.65 |
| Employees | 315 | LT Debt/Eq | 0.00 | Earnings | Nov 09 | SMA200 | 18.41% | Avg Volume | 1.23M | Price | 36.95 |
| IPO Date | Jun 21, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -19.26% 0.00% | Net Debt/EBITDA | 1.48 | Volume | 2,941,289 | Change | -1.86% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-21-26 | Reiterated | HC Wainwright & Co. | Buy | $51 → $40 |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | $50 |
| Dec-18-25 | Reiterated | Guggenheim | Buy | $44 → $41 |
| Oct-14-25 | Initiated | Truist | Hold | $16 |
| Apr-22-25 | Downgrade | UBS | Buy → Neutral | |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform | |
| Sep-10-24 | Reiterated | HC Wainwright & Co. | Buy | $51 |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform | $46 |
| May-30-24 | Reiterated | Guggenheim | Buy | $48 |
| May-30-24 | Reiterated | Piper Sandler | Overweight | $57 |
Latest News· Times ET
Sep-17-26
Sep-10-26
Sep-10-2608:52AM
Aug-26-26
Aug-19-26
Aug-19-2603:52PM
Aug-17-26
Aug-13-26
Aug-06-26
11:05AM
Immunovant Q1 Earnings Call Highlightsmarketbeat.com
08:26AM
03:00AM
Aug-04-26
Jul-27-26
Jul-27-2607:09PM
Jul-21-26
Jul-20-26
Jul-20-2601:08PM
Jun-30-26
Company
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2026 3/31/2026 | FY 2025 3/31/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | FY 2018 3/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 76 | 77 | 57 | — | — | — | — | — | — | |
| Research and Development | 457 | 361 | 213 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -533 | -438 | -270 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 28 | 25 | 11 | — | — | — | — | — | — | |
| Net Income Before Taxes | -505 | -413 | -259 | — | — | — | — | — | — | |
| Income Taxes | 0 | 1 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | -506 | -414 | -259 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -506 | -414 | -259 | — | — | — | — | — | — | |
| Net Income | -506 | -414 | -259 | — | — | — | — | — | — | |
| EPS (Recurring) | -2.77 | -2.73 | -1.88 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.77 | -2.73 | -1.88 | — | — | — | — | — | — | |
| EPS (Diluted) | -2.77 | -2.73 | -1.88 | — | — | — | — | — | — | |
| EBITDA | -505 | -413 | -259 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 182 | 152 | 138 | — | — | — | — | — | — | |
| Market Capitalization | 4,521 | 2,598 | 4,459 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Pande Atul | Director | Aug 28 '26 | Option Exercise | 8.43 | 1,500 | 12,645 | 118,231 | Aug 28 |
| Pande Atul | Director | Aug 28 '26 | Sale | 43.27 | 1,500 | 64,905 | 116,731 | Aug 28 |
| Gloria Melanie | Chief Operating Officer | Aug 20 '26 | Sale | 44.16 | 3,056 | 134,953 | 219,301 | Aug 21 |
| Pande Atul | Director | Jul 24 '26 | Option Exercise | 8.43 | 1,500 | 12,645 | 118,231 | Jul 24 |
| Pande Atul | Director | Jul 24 '26 | Sale | 39.80 | 1,500 | 59,700 | 116,731 | Jul 24 |
| Stout Jay S | Chief Technology Officer | Jul 23 '26 | Sale | 38.69 | 2,857 | 110,537 | 205,341 | Jul 24 |
| Girao Tiago | Chief Financial Officer | Jul 23 '26 | Sale | 38.69 | 6,798 | 263,015 | 240,798 | Jul 24 |
| Van Tuyl Christopher | Chief Legal Officer | Jul 08 '26 | Sale | 39.55 | 1,206 | 47,702 | 179,391 | Jul 10 |
| Stout Jay S | Chief Technology Officer | Jul 08 '26 | Sale | 39.55 | 3,487 | 137,924 | 208,198 | Jul 10 |
| Gloria Melanie | Chief Operating Officer | Jul 08 '26 | Sale | 39.55 | 2,036 | 80,532 | 222,357 | Jul 10 |
| Venker Eric | Chief Executive Officer | Jul 02 '26 | Sale | 38.48 | 3,092 | 118,980 | 254,280 | Jul 06 |
| Venker Eric | Chief Executive Officer | Jul 01 '26 | Option Exercise | 14.46 | 92,188 | 1,333,038 | 344,001 | Jul 06 |
| Gloria Melanie | Chief Operating Officer | Jun 26 '26 | Sale | 38.31 | 17,714 | 678,605 | 224,393 | Jun 26 |
| Stout Jay S | Chief Technology Officer | Jun 26 '26 | Sale | 38.31 | 40,000 | 1,532,310 | 211,685 | Jun 26 |
| Van Tuyl Christopher | Chief Legal Officer | Jun 26 '26 | Option Exercise | 15.20 | 17,824 | 270,925 | 198,421 | Jun 26 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.